Nitrofurantoin Olikla (Nitrofurantoin, Macrocrystalline)

• Nitrofurantoin Olikla is used to treat bacterial infections of the lower urinary tract.
• Uncomplicated urinary tract infection (cystitis): eradicates susceptible uropathogens, reduces bacterial load, and relieves dysuria, frequency, and urgency.
• Acute uncomplicated lower urinary tract infection: provides rapid bactericidal activity to prevent symptom worsening and potential upper tract involvement.
• Urinary tract infection caused by susceptible bacteria: achieves swift bacterial clearance in the bladder, facilitating symptom resolution and reducing recurrence risk.

• Nitrofurantoin exerts its antibacterial effect by entering bacterial cells and inhibiting enzymes involved in carbohydrate metabolism, particularly bacterial flavoproteins. This disruption interferes with the synthesis of nucleic acids and cell wall components, leading to bactericidal activity against common urinary pathogens such as Escherichia coli, Enterococcus spp., and Staphylococcus saprophyticus. The drug is concentrated in urine, where it reaches concentrations sufficient to maintain its activity throughout the dosing interval.

Nitrofurantoin Olikla may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild gastrointestinal upset that may resolve with continued therapy.
• Loss of appetite: decreased desire to eat, often transient.
• Headache: mild to moderate head discomfort.
• Diarrhea: loose stools, usually self‑limiting.

Serious or Rare Side Effects

• Pulmonary toxicity: interstitial pneumonitis or fibrosis requiring discontinuation.
• Hepatic injury: hepatitis or liver enzyme elevation.
• Severe allergic reactions: rash, urticaria, or anaphylaxis.
• Hemolytic anemia: especially in patients with G6PD deficiency.

Before prescribing Nitrofurantoin Olikla, clinicians should consider several safety precautions.

• Renal function: assess creatinine clearance and avoid use in patients with markedly reduced renal function.
• Pregnancy: avoid during the first trimester and near term unless benefits outweigh potential risks.
• Elderly patients: monitor for signs of toxicity and adjust therapy as needed.
• Drug interactions: review concomitant medications for potential absorption or metabolic interactions.
• Store at room temperature: keep in the original packaging, protect from moisture and heat.

Nitrofurantoin Olikla can interact with other medicines, affecting its absorption or safety profile.

Major Interactions (Avoid)

• Antacids containing magnesium or aluminum: significantly reduce nitrofurantoin absorption.
• Probenecid: may increase nitrofurantoin plasma concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely)

• Warfarin: nitrofurantoin may potentiate anticoagulant effect, requiring INR monitoring.
• Diabetes medications: may alter glucose control, necessitating blood sugar checks.
• Other antibiotics: concurrent use may lead to antagonistic effects or increased adverse events.